

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Q4 2022 QTD - Income Before Tax by Segment from Continuing Operations

(Dollars in Millions)	Pharmaceutical	MedTech	Unallocated	Worldwide Total
Reported Income Before Tax by Segment from Continuing Operations	\$ 3,223	806	(189)	3,840
% to Sales	24.5 %	11.9 %	(0.9)%	19.3 %
Intangible asset amortization expense	717	260	—	977
In-process research and development Impairments	173	—	—	173
Litigation Related	76	136	50	262
Loss/(gain) on securities	23	(17)	—	6
Restructuring related	31	88	—	119
Acquisition, integration and divestiture related	(104)	300	—	196
Medical Device Regulation	—	88	—	88
COVID-19 Vaccine related costs	821	—	—	821
Adjusted Income Before Tax by Segment from Continuing Operations	\$ 4,960	1,661	(139)	6,482
% to Sales	37.7 %	24.5 %	(0.7)%	32.5 %

Q4 2022 YTD - Income Before Tax by Segment from Continuing Operations

(Dollars in Millions)	Pharmaceutical	MedTech	Unallocated	Worldwide Total
Reported Income Before Tax by Segment from Continuing Operations	\$ 15,647	4,447	(735)	19,359
% to Sales	29.8 %	16.2 %	(0.9)%	24.2 %
Intangible asset amortization expense	2,911	1,033	—	3,944
In-process research and development Impairments	783	—	—	783
Litigation Related	104	612	150	866
Loss/(gain) on securities	696	(6)	—	690
Restructuring related	63	309	—	372
Acquisition, integration and divestiture related	(104)	300	—	196
Medical Device Regulation	—	296	—	296
COVID-19 Vaccine related costs	1,474	—	—	1,474
Other	—	—	(7)	(7)
Adjusted Income Before Tax by Segment from Continuing Operations	\$ 21,574	6,991	(592)	27,973
% to Sales	41.0 %	25.5 %	(0.7)%	35.0 %